Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program

Matsumoto, Koji; Yaegashi, Nobuo; Iwata, Takashi; Yamamoto, Keizô; Aoki, Yoichi; Okadome, Masao; Ushijima, Kimio; Kamiura, Shoji; Takehara, Kazuhiro; Horie, Koji; Tasaka, Nobutaka; Sonoda, Kenzo; Takei, Yuji; Konnai, Katsuyuki; Katabuchi, Hidetaka; Nakamura, Keiichiro; Ishikawa, Masatoshi; Watari, Hidemichi; Yoshida, Hiroyuki; Matsumura, Noriomi; Shigeta, Shogo; Takahashi, Fumiaki; Noda, Kiichiro; Yoshikawa, Hiroyuki

doi:10.1111/cas.14212

Cited by 26 publications

(41 citation statements)

References 27 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this cohort, Other hrHPV infection was most prevalent, accounting for 79.9% of hrHPV infections, and contributed to substantial cytological abnormalities as well as large proportions of CIN2/CIN3 (62.7% and 43.9%, respectively) over 3-year follow-up. With the advent of the vaccine era, prevalence of HPV16/18 infections and related CIN2+ rate are expected to decline, both in vaccinated women and unvaccinated women due to herd protection 21 , 22 . Furthermore, the eradication of HPV16/18 could lead to a relative increase in prevalence of Other hrHPV types and related CIN2+ rate 23 .…”

Section: Discussionmentioning

confidence: 99%

Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data

Song

Ai-min

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objectives: This study aimed to describe the study design, and to analyze the type-specific distribution of cervical high-risk human papillomavirus (hrHPV) infection and its association with cytological and histological results in a large population-based screening program in Buji Street, Shenzhen, China. Methods: A total of 10,186 women aged 21-70 years were co-tested by Cobas4800 HPV assay and liquid-based cytology. Women were referred to colposcopy by virtue of being HPV16/18-positive, Other hrHPV-positive/ cytology >ASCUS, or HPV-negative/ cytology >LSIL. Three-year histological follow-up data were recorded. Results: The overall prevalence of hrHPV infection was 11.1%; among them, the highest type was Other hrHPV (8.9%), followed by HPV16 (1.6%) and HPV18 (0.6%). Moreover, the prevalence of hrHPV and that of HPV16 increased with cytological severity (Ptrend <0.001). In the baseline phase, 106 women had cervical intraepithelial neoplasia 2/3 (CIN2/3) and six had cervical cancers. During 3-year follow-up, 12 cases of CIN2/3 and no cancers were identified. For HPV16-positive women with normal cytology, the baseline risks of CIN2/3 or worse (CIN2+/CIN3+) were 15.5% (7.0-23.9%) and 4.2% (1.4-8.5%) respectively. For Other hrHPV-positive women with normal cytology, the cumulative 3-year risks of CIN2+/CIN3+ were 3.1% (1.0-5.2%) and 0.7% (0.3-2.1%) respectively. Strikingly, 75.8% (322/425) of abnormal cytology and 50.9% (29/57) HSIL cytology were attributed to Other hrHPV infection in HPV-positive women. Similarly, Other hrHPV infection led to large proportions of CIN2 (62.7%) and CIN3+ (43.9%) over 3-year follow-up. Conclusions: The co-testing modality is a feasible, effective and safe option for cervical cancer screening in urban population. Great importance should also be attached to 'genotypes excluding HPV16/18' and separate detection of each genotype when considering screening and vaccination strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data

Song

Ai-min

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…HPV vaccine surveillance (Unger et al 2009), while the Roche LA assay has been used in numerous studies of HPV epidemiology, screening and vaccination (Wheeler et al 2006;Kitchener et al 2011;Castle et al 2011;Markowitz et al 2013;Garland et al 2018;Matsumoto et al 2019;Onuki et al 2020). PGMY-CHUV can detect 31 individual HPV genotypes at a much lower cost (Estrade et al 2011), but requires proficient skills of laboratory work and strict quality control for the reagents and membranes.…”

Section: Discussionmentioning

confidence: 99%

“…Based on LA genotyping results, the MINT study I reported a significant reduction in cervical precancer attrib-utable to HPV16/18 among vaccinated patients from 2012 to 2017 (Matsumoto et al 2019). To monitor long-term changes in the prevalence of HPV genotypes in Japan, the MINT study II is now in progress using PGMY-CHUV.…”

Section: Discussionmentioning

confidence: 99%

“…HPV genotyping was conducted for 5,045 women using the commercially available Linear Array (LA) assay (Roche Molecular Systems, Pleasanton, CA, USA). The MINT study I assessed the populationlevel impact of the current HPV16/18 vaccines (Matsumoto et al 2017(Matsumoto et al , 2019 and attributed the contribution of individual HPV genotypes to cervical cancer and precancer in Japan (Onuki et al 2020). To further monitor the long-term impact of HPV vaccination in Japan, we have recently initiated the MINT study II using nearly the same study design in April 2019 (UMIN Clinical Trails Registry: UMIN000038883).…”

Section: Introductionmentioning

confidence: 99%

“…The LA assay, which uses PCR-primers (PGMY09/11) to amplify a subregion of the L1 gene of mucosal HPVs, has been the gold standard for assessing new HPV genotyping assays for many years (Castle et al 2008;Dalstein et al 2009;Estrade et al 2011;Demarco et al 2018;Wagner et al 2019). LA has also been extensively used in research on HPV epidemiology, cervical cancer screening and vaccine surveillance (e.g., ALTS trial [Wheeler et al 2006], ARTISTIC trial [Kitchener et al 2011], ATHENA study [Castle et al 2011], VACCINE study [Garland et al 2018] and MINT study I [Matsumoto et al 2019]), but was discontinued in December 2019. In the MINT study II, we have selected an alternative HPV genotyping method based on PCR with the PGMY09/11 primers and reverse blotting hybridization with genotype-specific probes (hereafter designated as PGMY-CHUV).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine

Kukimoto

Matsumoto

Takahashi

et al. 2020

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

In Japan, a bivalent human papillomavirus (HPV) vaccine against carcinogenic HPV16/18 was licensed in 2009, and a quadrivalent vaccines against HPV16/18 and non-carcinogenic HPV6/11 was licensed in 2011. Recently, the next-generation 9-valent vaccine targeting HPV6/11/16/18/31/33/45/52/58 has been approved. Accurate HPV genotyping is essential for HPV vaccine research and surveillance. The Roche Linear Array (LA) has long been a standard assay for HPV genotyping, but its recent product discontinuation notice has urged us to introduce an alternative assay with comparable performance. In the present study, an in-house HPV genotyping assay that employs PCR with PGMY09/11 primers and reverse blotting hybridization (PGMY-CHUV) was compared with LA to assess genotype-specific agreement. A total of 100 cervical precancer specimens were subjected to both PGMY-CHUV and LA. For detection of genotypes included in the 9-valent vaccine, PGMY-CHUV completely agreed with LA for detection of HPV6, HPV11, HPV16, HPV18, HPV33 and HPV45, and showed near-complete agreement for HPV31 and HPV58 (98% and 99%, respectively). Moreover, PGMY-CHUV detected a significantly higher prevalence of HPV52 than LA (22% vs. 14%, P = 0.008 by McNemar's exact test), with 92.0% overall agreement, 63.6% positive agreement and a kappa value of 0.73. Most (87.5%) of HPV52 discordant cases involved mixed infections with HPV35 or HPV58. In conclusion, while the two assays present equivalent data for assessing the effectiveness of the bivalent and quadrivalent vaccines, PGMY-CHUV is more suitable for evaluating the impact of the current 9-valent vaccine because of its superior detection of HPV52 in co-infection cases.

show abstract

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan

Yagi,

Ueda,

Oka

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceThe Ministry of Health, Labour, and Welfare (MHLW) of Japan aggregates human papillomavirus (HPV) vaccination data across Japan for each fiscal year (FY) by age at vaccination. Birth FY (BFY)–specific vaccination coverage remains unknown.ObjectiveTo calculate the BFY-specific vaccination coverage for each FY and the cumulative first-dose coverage for each BFY in Japan, to understand the generation-specific vaccination coverage, and to estimate the cumulative first-dose coverage of each BFY that would be achieved by FY 2028 vs World Health Organization (WHO) targets.Design, Setting, and ParticipantsIn this cross-sectional study, MHLW-published national age-specific HPV vaccination numbers and demographic data for female individuals were used to calculate the BFY-specific first-dose coverage for each FY and the BFY-specific cumulative first-dose coverage. It was assumed that the BFYs 2007 to 2012 vaccination coverage in FY 2023 to 2028 would remain the same as the vaccination coverage of the same grade in FY 2022 to estimate the cumulative first-dose coverage that would be achieved by FY 2028. Data analysis was performed from December 2023 to January 2024.ExposureTwo MHLW policy changes were the government’s suspension of proactive recommendation for HPV vaccination in June 2013 and the government’s resumption of proactive recommendation for HPV vaccination in April 2022.Main Outcomes and MeasuresThe primary outcome was generation-specific vaccination coverage among female individuals born in BFYs 1994 to 2010 in FYs 2010 to 2022, calculated using reconfigured published data.ResultsIn this study of vaccination data for 9 414 620 female individuals, the generation-specific vaccination coverage was 71.96% for the vaccination generation (BFYs 1994-1999), 4.62% for the vaccine-suspension generation (BFYs 2000-2003), 16.16% for the generation that received information individually (BFYs 2004-2009), and 2.83% for the vaccine-resumed generation (BFY 2010). HPV routine vaccination coverage was extremely low in BFYs 2000 to 2010 (0.84%-25.21%) vs BFYs 1994 to 1999 (53.31%-79.47%). The cumulative first-dose coverage that was estimated to be achieved in the vaccine-resumed generation by FY 2028 plateaued at 43.16%.Conclusions and RelevanceEven after the resumption of MHLW’s proactive recommendations, HPV vaccination coverage has only minimally recovered in Japan. The cumulative first-dose coverage that was estimated to be achieved in the vaccine-resumed generation by FY 2028 is below the WHO target. These findings reveal that stronger cervical cancer control measures are required, particularly for the vaccine-resumed generation, which will plateau at approximately one-half the WHO target values.

show abstract

Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program

Cited by 26 publications

References 27 publications

Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data

Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data

Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan

Contact Info

Product

Resources

About